Article info

Original research
Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies

Authors

  1. Correspondence to Gabrielle Leclercq; gabrielle.leclercq{at}roche.com
View Full Text

Citation

Leclercq G, Haegel H, Schneider A, et al
Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies

Publication history

  • Accepted July 5, 2021
  • First published July 29, 2021.
Online issue publication 
July 29, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.